Prophase Labs Stock Today
| PRPH Stock | USD 0.16 0.01 5.88% |
PerformanceWeakest
| Odds Of DistressStrong
|
ProPhase Labs is trading at 0.16 as of the 17th of February 2026. This is a 5.88 percent decrease since the beginning of the trading day. The stock's open price was 0.17. ProPhase Labs has a very high chance of experiencing financial distress in the next few years of operation. It has also generated negative returns for investors over the last 90 days. The performance scores are derived for the period starting the 19th of November 2025 and ending today, the 17th of February 2026. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 16th of January 1997 | Category Healthcare | Classification Health Care |
ProPhase Labs, Inc. engages in the research, development, manufacture, distribution, marketing, and sale of over the counter consumer healthcare products and dietary supplements in the United States. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. The company has 4.74 M outstanding shares of which 300.24 K shares are at this time shorted by private and institutional investors with about 0.08 trading days to cover. More on ProPhase Labs
Moving together with ProPhase Stock
| 0.84 | KG | Kestrel Group Symbol Change | PairCorr |
Moving against ProPhase Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
ProPhase Stock Highlights
| Chairman and CEO | Ted Karkus | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Pharmaceuticals, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite Total, Health Care, Pharmaceuticals, Drug Manufacturers—Specialty & Generic, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsDebt leverage enables ProPhase Labs to amplify potential investment gains using borrowed funds. Evaluating debt relative to total assets helps investors assess ProPhase Labs' financial structure and understand the extent to which ProPhase Labs' operations depend on creditor capital.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
ProPhase Labs (PRPH) is traded on NASDAQ Exchange in USA and employs 96 people. ProPhase Labs is listed under Pharmaceuticals category by Fama And French industry classification. The company currently falls under 'Nano-Cap' category with a current market capitalization of 724.76 K. ProPhase Labs conducts business under Pharmaceuticals sector and is part of Health Care industry. The entity has 4.74 M outstanding shares of which 300.24 K shares are at this time shorted by private and institutional investors with about 0.08 trading days to cover.
ProPhase Labs currently holds about 27.5 M in cash with (17.54 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.72, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ProPhase Labs Probability Of Bankruptcy
Ownership AllocationProPhase Labs holds 5.05 pct. of its outstanding shares held by insiders and 4.06 pct. owned by third-party entities.
Check ProPhase Ownership Details
ProPhase Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Virtu Financial Llc | 2025-06-30 | 40.4 K | |
| Two Sigma Securities, Llc | 2025-06-30 | 37.8 K | |
| Bank Of New York Mellon Corp | 2025-06-30 | 37.1 K | |
| United Capital Management Of Ks | 2025-06-30 | 34.7 K | |
| Blackrock Inc | 2025-06-30 | 28 K | |
| Bank Of America Corp | 2025-06-30 | 27.2 K | |
| Northern Trust Corp | 2025-06-30 | 23.2 K | |
| Bkb Wealth Advisors, Llc | 2025-06-30 | 19.6 K | |
| Hpm Partners Llc | 2025-06-30 | 19 K | |
| Vanguard Group Inc | 2025-06-30 | 408.3 K | |
| Geode Capital Management, Llc | 2025-06-30 | 259.1 K |
ProPhase Labs Historical Income Statement
ProPhase Stock Against Markets
ProPhase Labs Corporate Management
| Billy White | Consultant | Profile | |
| Stu Hollenshead | Chief Officer | Profile | |
| Sergio Miralles | Executive Diagnostics | Profile | |
| Steven CPA | Chief Officer | Profile | |
| Kevin Quinn | Chief Genomics | Profile |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in ProPhase Labs. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. For more detail on how to invest in ProPhase Stock please use our How to Invest in ProPhase Labs guide.You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Is there potential for Pharmaceuticals market expansion? Will ProPhase introduce new products? Factors like these will boost the valuation of ProPhase Labs. Anticipated expansion of ProPhase directly elevates investor willingness to pay premium valuations. Understanding fair value requires weighing current performance against future potential. All the valuation information about ProPhase Labs listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.95) | Earnings Share (19.80) | Revenue Per Share | Quarterly Revenue Growth (0.38) | Return On Assets |
The market value of ProPhase Labs is measured differently than its book value, which is the value of ProPhase that is recorded on the company's balance sheet. Investors also form their own opinion of ProPhase Labs' value that differs from its market value or its book value, called intrinsic value, which is ProPhase Labs' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because ProPhase Labs' market value can be influenced by many factors that don't directly affect ProPhase Labs' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
It's important to distinguish between ProPhase Labs' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding ProPhase Labs should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Meanwhile, ProPhase Labs' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.